# Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94

> **NCT00617032** · PHASE1 · COMPLETED · sponsor: **Targeted Genetics Corporation** · enrollment: 15 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 gene therapy vector
- **GENETIC:** tgAAC94 placebo

## Key facts

- **NCT ID:** NCT00617032
- **Lead sponsor:** Targeted Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2008-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617032, "Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00617032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*